The Long-Acting/Extended Release Antiretroviral Research Resource Program (LEAP) provides broadly based scientific support to accelerate the development of novel drugs, formulations, and technologies for the treatment and prevention of HIV and related epidemics. The LEAP Process to facilitate drug and formulation development begins with a landscape analysis, identifying knowledge gaps and barriers, simulating best product characteristics, communicating potential solutions, and then tracking product outcomes. The Program serves as a focal point for the global conversation on the development of LA/ER formulations, and has brought many of the world's key stakeholders into this conversation. LEAP's seminal accomplishments include foundational input for FDA draft guidance on the development of LA/ER formulations for HIV; promoting development of the first candidate LA/ER formulations for tuberculosis and malaria; organizing the first conference on use of LA/ER formulations for HIV in children, adolescents, and pregnant women; producing the first publically accessible website devoted to LA/ER anti-infective products and strategies; and supporting development of novel devices like anti-HIV implants and microneedles through its Modeling and Simulation Core. Established in 2015, LEAP is now poised to apply its acquired expertise to new challenges. During the next five years, we will leverage the infrastructure we have created to: 1) apply our scientific resources to identify and facilitate development of the most promising new drugs and drug delivery platforms in order to overcome the limitations of available products; 2) build upon our existing modeling and simulation expertise to develop better ways to more rapidly identify those approaches with the most desirable pharmacologic properties; and 3) expand the scope of LEAP to include diseases that overlap the HIV epidemic, where the availability of LA/ER drugs and formulations could most profoundly affect treatment and prevention ? specifically, tuberculosis, hepatitis B virus, and hepatitis C virus infections. Expected outcomes include an increased number of new long-acting drugs and formulations in preclinical and clinical development, enhanced funding mechanisms to bring more such products into testing, and accelerated pathways for more rapid translation of laboratory-based research into clinical trials and eventual drug approvals.

Public Health Relevance

Current treatment and prevention of HIV, tuberculosis, and viral hepatitis requires taking pills every day for long periods of time. LEAP encourages the development of long-acting injectable and implantable drugs by providing access to scientific, pharmaceutical, regulatory, and community-based experts and services. This could results in the replacement of daily oral regimens with products given as infrequently as once per year.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Resource-Related Research Projects (R24)
Project #
2R24AI118397-06A1
Application #
10079160
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Livnat, Daniella
Project Start
2015-05-16
Project End
2025-06-30
Budget Start
2020-07-16
Budget End
2021-06-30
Support Year
6
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21205
Weld, Ethel D; Rana, Md Sohel; Dallas, Ronald H et al. (2018) Interest of Youth Living with HIV in Long-Acting Antiretrovirals. J Acquir Immune Defic Syndr :
Bakshi, Rahul P; Tatham, Lee M; Savage, Alison C et al. (2018) Long-acting injectable atovaquone nanomedicines for malaria prophylaxis. Nat Commun 9:315
Rajoli, R K R; Podany, A T; Moss, D M et al. (2018) Modelling the long-acting administration of anti-tuberculosis agents using PBPK: a proof of concept study. Int J Tuberc Lung Dis 22:937-944
Flexner, Charles (2018) Antiretroviral implants for treatment and prevention of HIV infection. Curr Opin HIV AIDS 13:374-380
Swindells, S; Siccardi, M; Barrett, S E et al. (2018) Long-acting formulations for the treatment of latent tuberculous infection: opportunities and challenges. Int J Tuberc Lung Dis 22:125-132
Rajoli, Rajith K R; Back, David J; Rannard, Steve et al. (2018) In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents. Clin Pharmacokinet 57:255-266
Flexner, Charles W; Clayden, Polly; Venter, Willem D F (2017) Why a universal antiretroviral regimen? Curr Opin HIV AIDS 12:315-317
Jacobson, Jeffrey M; Flexner, Charles W (2017) Universal antiretroviral regimens: thinking beyond one-pill-once-a-day. Curr Opin HIV AIDS 12:343-350
Owen, Andrew; Rannard, Steve (2016) Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy. Adv Drug Deliv Rev 103:144-56
Nelson, Antoinette G; Zhang, Xiaoping; Ganapathi, Usha et al. (2015) Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment. J Control Release 219:669-680